Guided Therapeutics (GTHP) Gross Margin (2012 - 2025)

Guided Therapeutics has disclosed Gross Margin across 14 years of filings, most recently posting 77.63% for Q4 2025.

• In Q4 2025, Gross Margin rose 27763.0% year-over-year to 77.63%; the TTM figure through Jun 2026 stood at 75.85% (up 1059.0% YoY), while the FY2025 annual figure was 74.45%, up 4587.0% from the prior year.
• Gross Margin came in at 77.63% for Q4 2025 at Guided Therapeutics, up from 58.33% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2021 to a low of 200.0% in Q4 2024.
• Average Gross Margin over 5 years is 36.54%, with a median of 67.09% recorded in 2024.
• Year-over-year, Gross Margin tumbled 27167 bps in 2021 and jumped 27763 bps in 2025.
• Over 5 years, Gross Margin stood at 68.33% in 2021, then surged by 46 bps to 100.0% in 2022, then plunged by 50 bps to 50.0% in 2023, then sank by 500 bps to 200.0% in 2024, then soared by 139 bps to 77.63% in 2025.
• Per Business Quant data, the three most recent Gross Margin figures were 77.63% in Q4 2025, 58.33% in Q3 2025, and 67.52% in Q2 2025.